Bitran Jacob D, Klein Leonard, Link Doreen, Kosirog-Glowacki Jane, Stewart Cynthia, Raack David, Sheahan Pat, Lisowski Josephine, Rowen Josie
Department of Medicine, Division of Hematology/Oncology, Lutheran General Hospital Cancer Care Center, 1700 Luther Lane, Park Ridge, IL 60068, USA.
Biol Blood Marrow Transplant. 2003 Jun;9(6):383-8. doi: 10.1016/s1083-8791(03)00099-5.
Eleven elderly patients (older than 65 years) with relapsed large cell lymphoma were treated with high-dose myeloablative therapy and autologous peripheral blood progenitor cell support (ABMT). All 11 patients were in sensitive relapse at the time of ABMT. Treatment-related mortality was 9%. Median CD34 cell collection was 4.8 x 10(6) cells/kg. Median time to hematologic recovery was 11 days for granulocytes (range, 9 to 16 days) and 18 days for platelets (range, 14 to 42 days). Nine of 11 patients (81%) achieved a complete response following ABMT. Median time to treatment failure was 17 months. The 4-year disease-free and overall survival is projected to be 44%. When compared with a cohort of patients under age 65 years with sensitive relapsed large cell lymphoma treated with ABMT during the same time interval, disease-free and overall survival are comparable. ABMT is feasible, tolerable, and effective in elderly patients with relapsed large cell lymphoma with disease-free survival rates comparable to younger patients.
